RayzeBio inc (DELISTED) (RYZB:DL)
62.49
0.00 (0.00%)
USD |
NASDAQ |
Mar 06, 16:00
RayzeBio Net Income (Quarterly): -18.19M for Sept. 30, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
September 30, 2023 | -18.19M |
December 31, 2022 | -14.70M |
Date | Value |
---|---|
September 30, 2022 | -20.45M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-20.45M
Minimum
Sep 2022
-14.70M
Maximum
Dec 2022
-17.78M
Average
-18.19M
Median
Sep 2023
Net Income (Quarterly) Benchmarks
Bristol-Myers Squibb Co | 1.211B |
Karuna Therapeutics Inc (DELISTED) | -113.82M |
Ambrx Biopharma Inc (DELISTED) | -22.99M |
Pfizer Inc | 4.465B |
Mirati Therapeutics Inc (DELISTED) | -161.90M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 21.65M |
EPS Diluted (Quarterly) | -1.26 |
Enterprise Value | 3.204B |